Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study

Eleni Papakokkinou1,2, Daniel S Olsson1,2, Dimitrios Chantzichristos1,2

  • 1Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Insights

Patients with Cushing's disease (CD) face elevated risks of stroke, thromboembolism, and sepsis even after achieving remission. Long-term monitoring for these comorbidities is crucial for managing their health.

Area of Science:

  • Endocrinology
  • Internal Medicine
  • Public Health

Background:

  • Cushing's disease (CD) can lead to multisystem morbidity.
  • The long-term health implications of CD during remission are not fully understood.

Purpose of the Study:

  • To investigate the prevalence and incidence of comorbidities in patients with Cushing's disease.
  • To assess if elevated morbidity persists during long-term remission of CD.

Main Methods:

  • Retrospective nationwide study using the Swedish National Patient Register (1987-2013).
  • Included 502 patients with confirmed CD, analyzing medical records for diagnosis and remission status.
  • Calculated standardized incidence ratios (SIRs) comparing patients to the general population across different time periods: pre-diagnosis, diagnosis to 1-year post-remission, and long-term remission.

Main Results:

  • Before diagnosis, patients showed increased SIRs for myocardial infarction, fractures, and deep vein thrombosis.
  • From diagnosis to 1 year post-remission, elevated SIRs were observed for thromboembolism, stroke, and sepsis.
  • During long-term remission, SIRs remained significantly increased for thromboembolism, stroke, and sepsis.

Conclusions:

  • Cushing's disease patients experience a heightened risk of stroke, thromboembolism, and sepsis, persisting even after remission.
  • These findings underscore the necessity of proactive risk factor management and continuous follow-up for these comorbidities in CD survivors.
Abstract